Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Rhea-AI Summary
Roivant has scheduled an important investor webcast for Wednesday, March 19, 2025, at 8:00 AM ET to discuss important clinical trial results. The presentation will focus on two key areas:
- Results from the Phase 3 study of batoclimab in Myasthenia Gravis (MG)
- Initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The webcast will feature presentations from Pete Salzmann, CEO of Immunovant, and Matt Gline, CEO of Roivant. Investors can register for the event through the company's website, and the presentation will be archived for future viewing under the 'Events & Presentations' section at investor.roivant.com/news-events/events.
Positive
- None.
Negative
- None.
News Market Reaction – ROIV
On the day this news was published, ROIV gained 2.15%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When will Roivant (ROIV) present its batoclimab clinical trial results?
What clinical trial results will be discussed in Roivant's March 19 webcast?
How can investors access Roivant's March 19 clinical trial results webcast?
Which executives will present at Roivant's March 19 clinical trial results webcast?
